Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cognition Therapeutics, Inc. (CGTX : NSDQ)

• Company Description    Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE, N.Y. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $0.59 Daily Weekly Monthly 20 Day Moving Average: 1,280,804 shares Shares Outstanding: 89.35 (millions) Market Capitalization: $53.13 (millions) Beta: 1.25 52 Week High: $3.83 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.91% -39.15% 12 Week -57.53% -53.79% Year To Date -55.96% -52.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2500 Westchester Avenue - Purchase,NY 10577 USA ph: 412-481-2210 fax: - info@cogrx.com http://www.cogrx.com

• General Corporate Information    Officers Lisa Ricciardi - Chief Executive Officer and President Jack A. Khattar - Chairman John Doyle - Chief Financial Officer Aaron G. L. Fletcher - Director Brett P. Monia - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19243B102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/06/26 Share - Related Items Shares Outstanding: 89.35 Most Recent Split Date: (:1) Beta: 1.25 Market Capitalization: $53.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 88.24% vs. Previous Quarter: 66.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -104.27 09/30/25 - -150.10 06/30/25 - -251.23 ROA 12/31/25 - -69.64 09/30/25 - -95.88 06/30/25 - -130.75 Current Ratio 12/31/25 - 3.45 09/30/25 - 6.44 06/30/25 - 1.54 Quick Ratio 12/31/25 - 3.45 09/30/25 - 6.44 06/30/25 - 1.54 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 0.39 09/30/25 - 0.50 06/30/25 - 0.11 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©